Latest News

Barbara Burtness, MD, outlined the rationale behind OrigAMI-4 eligibility criteria and how tumor boards can select patients with HNSCC for amivantamab.

Barbara Burtness, MD, discussed strategies for managing skin reactions and MET-driven edema in head and neck cancer treated with subcutaneous amivantamab.

Barbara Burtness, MD, discussed the biological rationale for dual EGFR/MET targeting and how the OrigAMI-4 data may reshape treatment workflows for HNSCC.

Learning to engage in genuine, thoughtful dialogue is a powerful way to build trust and shared understanding across differences. It’s a skill especially important for those embarking on a career in healthcare where patient trust, team collaboration, and informed decision-making are paramount.

On July 30, 2026, Dr. Faye Rogers hosted the Biomedical Summer Undergraduate Research Fellowship Symposium.

In June, the Yale Cancer Center's Office of Collaborative Excellence celebrated the achievements of its trainees by hosting its inaugural End-of-Year Celebration, recognizing a year of scientific discovery and professional growth.

This summer, Yale Cancer Center's Cancer Research Training & Education Coordination (CRTEC) program welcomed the second cohort of the Future Deaf Scientists (FDS) Program, a four-week experience designed to introduce Deaf high school students to careers in cancer research, healthcare, and STEM.

From July 13–17, 2026, twelve high school students participated in "Cracking the Code of Cancer: Exploring HER2 Expression in Breast Cancer Through Protein Analysis," a week-long workshop offered through Yale Pathways to Science Summer Scholars, which introduces local students to STEM through immersive, hands-on learning experiences.

Researchers from Yale Cancer Center participated in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, where they presented the latest research advancements from Yale Cancer Center and Smilow Cancer Hospital.